181 related articles for article (PubMed ID: 10506635)
1. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience.
Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J
J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma.
Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J
Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex.
Hoffman DM; Figlin RA
World J Urol; 2000 Apr; 18(2):152-6. PubMed ID: 10854152
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex.
Daniels GA; Galanis E
Curr Opin Mol Ther; 2001 Feb; 3(1):70-6. PubMed ID: 11249734
[TBL] [Abstract][Full Text] [Related]
5. Technology evaluation: interleukin-2 gene therapy for the treatment of renal cell carcinoma.
Figlin RA; Parker SE; Horton HM
Curr Opin Mol Ther; 1999 Apr; 1(2):271-8. PubMed ID: 11715951
[TBL] [Abstract][Full Text] [Related]
6. Leuvectin Vical Inc.
Kaushik A
Curr Opin Investig Drugs; 2001 Jul; 2(7):976-81. PubMed ID: 11757801
[TBL] [Abstract][Full Text] [Related]
7. Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA.
Clark PR; Stopeck AT; Ferrari M; Parker SE; Hersh EM
Cancer Gene Ther; 2000 Jun; 7(6):853-60. PubMed ID: 10880015
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma.
Stopeck AT; Hersh EM; Akporiaye ET; Harris DT; Grogan T; Unger E; Warneke J; Schluter SF; Stahl S
J Clin Oncol; 1997 Jan; 15(1):341-9. PubMed ID: 8996161
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma.
Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R
Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology.
Belldegrun A; Tso CL; Zisman A; Naitoh J; Said J; Pantuck AJ; Hinkel A; deKernion J; Figlin R
Hum Gene Ther; 2001 May; 12(8):883-92. PubMed ID: 11387054
[TBL] [Abstract][Full Text] [Related]
14. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
15. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
16. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma.
Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L
Front Immunol; 2021; 12():778459. PubMed ID: 34777395
[TBL] [Abstract][Full Text] [Related]
18. Human gene therapy for melanoma: CT-guided interstitial injection.
Waddill W; Wright W; Unger E; Stopeck A; Akporiaye E; Harris D; Grogan T; Schluter S; Hersh E; Stahl S
AJR Am J Roentgenol; 1997 Jul; 169(1):63-7. PubMed ID: 9207502
[TBL] [Abstract][Full Text] [Related]
19. Metastatic renal cell carcinoma: CT-guided immunotherapy as a technically feasible and safe approach to delivery of gene therapy for treatment.
Suh RD; Goldin JG; Wallace AB; Sheehan RE; Heinze SB; Gitlitz BJ; Figlin RA
Radiology; 2004 May; 231(2):359-64. PubMed ID: 15128982
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
